GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Beginning Cash Position

Alpha Cognition (Alpha Cognition) Beginning Cash Position : $1.50 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Beginning Cash Position?

Alpha Cognition's Beginning Cash Position for the quarter that ended in Mar. 2024 was $1.50 Mil.

Alpha Cognition's quarterly Beginning Cash Position declined from Sep. 2023 ($1.22 Mil) to Dec. 2023 ($0.91 Mil) but then increased from Dec. 2023 ($0.91 Mil) to Mar. 2024 ($1.50 Mil).

Alpha Cognition's annual Beginning Cash Position increased from Dec. 2021 ($5.93 Mil) to Dec. 2022 ($11.30 Mil) but then declined from Dec. 2022 ($11.30 Mil) to Dec. 2023 ($2.09 Mil).


Alpha Cognition Beginning Cash Position Historical Data

The historical data trend for Alpha Cognition's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Beginning Cash Position Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beginning Cash Position
5.50 5.93 11.30 2.09

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 3.88 1.22 0.91 1.50

Alpha Cognition Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Alpha Cognition Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Alpha Cognition's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Cognition (Alpha Cognition) Business Description

Traded in Other Exchanges
Address
301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.